Andelyn Biosciences Partners with Hubble Therapeutics for AAV
Andelyn Biosciences Partners with Hubble Therapeutics for AAV Production
Andelyn Biosciences, Inc., a prominent cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has entered into a partnership with Hubble Therapeutics, LLC. This collaboration focuses on the manufacturing of clinical-grade adeno-associated virus (AAV) utilizing Andelyn's advanced suspension AAV Curator™ Platform, aimed at treating Leber Congenital Amaurosis 16 (LCA16).
Understanding LCA16 and Its Impact
LCA16 is characterized as a severe retinal dystrophy caused by mutations in the KCNJ13 gene, which significantly affects vision starting in early childhood. Children affected by this condition often show visual impairments within the first five years of life, which gradually leads to complete blindness. The FDA has recognized the urgency of this issue, granting HUB-101 both Rare Pediatric Disease Designation and Orphan Disease Designation. By optimizing and scaling up the manufacturing process for HUB-101, Andelyn aims to assist in the creation of GMP-grade plasmids and vectors, incorporating normal KCNJ13 gene copies.
Commitment to Pediatric and Adult Patients
Jeff Sabados, President of Hubble Therapeutics LLC, emphasized the strategic importance of finding top-tier partners like Andelyn Biosciences. He noted the commitment shown by Andelyn to the development of gene therapy solutions for both adult and pediatric patients grappling with LCA16. This partnership underscores a shared vision of alleviating the burdens faced by families impacted by this genetic condition.
The Role of Andelyn Biosciences
Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, expressed enthusiasm about their contribution to the HUB-101 project. He highlighted the importance of their role in providing the necessary clinical-grade materials while aiming to foster a pathway that demonstrates clinical benefits for patients involved in the LCA16 study. Andelyn's reputation as a leading and reliable CDMO is instrumental in accelerating various gene therapy programs, potentially offering new hope for individuals afflicted by debilitating diseases.
About Andelyn Biosciences, Inc.
Andelyn Biosciences operates as a comprehensive CDMO specializing in cell and gene therapies. With over two decades of expertise, the organization has successfully produced cGMP materials for more than 450 clinical batches and contributed to 75 global clinical trials. Situated across three facilities, Andelyn provides a full range of services to clients, from plasmid engineering and manufacturing to cGMP clinical and commercial production. Andelyn can integrate advanced technology with their configurable, data-driven AAV Curator™ Platform to enhance program efficiency and output quality.
About Hubble Therapeutics, LLC
Hubble Therapeutics, LLC, or HubbleTx, is a dedicated biotechnology company focused on developing cutting-edge gene therapy solutions, particularly for LCA16. Originating from rigorous research conducted at the University of Wisconsin-Madison, HubbleTX aims to tackle this debilitating condition by developing therapies designed to restore vision and improve patient quality of life. Their collaborative approach, combined with a commitment to clinical excellence, positions them uniquely to make significant advancements in this vital area of healthcare.
Frequently Asked Questions
What is the main focus of the partnership between Andelyn and Hubble?
The partnership aims to manufacture clinical-grade AAV for the treatment of Leber Congenital Amaurosis 16 (LCA16).
What is LCA16?
LCA16 is a severe retinal dystrophy caused by mutations in the KCNJ13 gene, leading to vision loss and gradual blindness.
How does Andelyn Biosciences contribute to this project?
Andelyn provides expertise in manufacturing AAV and developing GMP-grade plasmids necessary for the clinical trials of HUB-101.
What designations has HUB-101 received?
HUB-101 has been granted Rare Pediatric Disease Designation and Orphan Disease Designation from the FDA.
What is the goal of Hubble Therapeutics?
Hubble Therapeutics aims to restore vision and improve life quality for individuals affected by LCA16 through innovative gene therapy solutions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Fanhua Strengthens Leadership with New Appointments
- Primis Financial Corp. Updates on Compliance Status with Nasdaq
- LandBridge Set for Key Earnings Call and Performance Insights
- Coveo Sets Conference Call for Fiscal Second Quarter Results
- General Motors Gains Momentum Amid Positive Analyst Forecasts
- Talisker Resources Secures $21.5 Million for Mining Expansion
- Iterum Therapeutics Set to Shine at the Upcoming Summit
- HPH Board Sees Renewed Leadership with New Appointments
- Banana Flour Market Thrives with AI Innovations and Growth Trends
- Revance Therapeutics: Investigating Possible Securities Fraud
Recent Articles
- Resolution Copper Grants $750K to Boyce Thompson Arboretum
- Georgia-Pacific Announces Major Investment in Dixie Tableware
- Transforming Road Infrastructure: A Bold Partnership Approach
- Soaring Demand for Single-cell Technologies in Healthcare Sector
- DoubleVerify Faces Market Headwinds With Stock at 52-Week Low
- Disney World Closes Florida Theme Park Ahead of Hurricane
- Resolution of Bitfinex Hack Finally Revealed After Years
- Senator Urges Federal Action as IV Solutions Faces Shortages
- Uber Stays Strong Amid Tesla's Robotaxi Threat and Changes
- The Growth Journey of Analog Devices Stock Over 20 Years
- Discovering Five-Year Gains from Riot Platforms Investments
- Nokia's Q3 Earnings Outlook: Can Innovation Drive Growth?
- Legal Action Alert: Class Action Filed Against Paragon 28, Inc.
- Pomerantz Law Firm Files Class Action Against AMMO, Inc. (POWW)
- Bumble Faces Class Action Amidst Challenging Financial Results
- Coinbase Faces Class Action Over Alleged Misconduct and Fraud
- New Fortress Energy Faces Class Action Lawsuit Amid Concerns
- Top Stocks Making Waves in the Market Today, Including IBM
- Tricoci University Elevates Beauty Education with New Wellness Program
- Fuel Shortages Escalate as Hurricane Milton Approach Looms
- AZTA Stock Hits New Low: A Closer Look at Recent Changes
- aTyr Pharma's Optimistic Trial Data Strengthens Market Position
- Google Faces Growing Legal Challenges in Antitrust Matters
- Key Measures to Ensure Safety in the Aviation Parts Supply Chain
- Remembering Ratan Tata: Legacy of Innovation and Growth
- Coinbase Enhances User Experience with Bitcoin Taproot Activation
- Exploring Promising Health Care Stocks for Investment
- HII Takes Lead on Groundbreaking Microelectronics Project
- Transom Capital Introduces Artivo Surfaces for Flooring Leadership
- Aedifica NV/SA Announces Important Transparency Notification
- Exploring Analog Devices' New Offerings and Market Potential
- Insight into Recent Options Trends for Ford Motor Co.
- Understanding Options Trends for Lululemon Athletica Stock
- Investor Sentiment and Activity: Qualcomm Insights
- Recent Fed Minutes Highlight Interest Rate Discussions Amid Growth
- A Closer Look at Costco's Performance and Future Outlook
- U.S. Stock Market Shows Resilience Amid Oil Inventory Surge
- Exciting Offers from TN Nursery to Kick Off Fall Gardening Season
- Kroger Unveils Halloween Candy Guide and Spooky Recipes
- Aequum Capital Boosts Pet Product Distributor with $15MM Credit
- Usher Shines Bright: Celebrating Afterschool Programs Nationwide
- Mitchell Hooper Joins Team MUTANT – A New Era in Strength Training
- Discover Perfect Day Mexico: A Stunning Addition to Vacations
- Revolutionizing Healthcare Operations with AI Strategies
- Federal Reserve's Rate Cut Plans: Insights from the Minutes
- Boeing Faces Challenges Amid Contract Withdrawal and Strike
- InterDigital and Lenovo Reach Patent Licensing Agreement
- Michael Anthony Guarino Joins Peapack-Gladstone Bank Team
- Affordable Drug Access for Medicare Recipients Under New Initiative
- Analysts Assess DOJ's Measures on Alphabet's Search Practices